Format

Send to

Choose Destination
Health Care Financ Rev. 1999 Spring;20(3):55-62.

Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.

Author information

1
Office of Strategic Planning, Health Care Financing Administration, Baltimore, MD 21244, USA. jgreer@hcfa.gov

Abstract

In this article the authors present descriptive data showing trends in human recombinant erythropoietin (EPO) doses, charges, and patient hematocrits from the fourth quarter of calendar year 1989 to the first quarter of 1998 for all recipients and recent data for patients treated by in-center hemodialysis. In 1997 nearly all in-center hemodialysis patients received EPO regularly at an average cost per recipient of $6,245 per year for total allowed charges of $842.2 million per year. The study shows that policy changes may have both anticipated and unanticipated effects on medical practice.

PMID:
10558020
PMCID:
PMC4194623
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center